ATE550033T1 - Fusionsproteine des reproduktiven und respiratorischen syndrom virus aus dem schwein als prrs impfstoff - Google Patents

Fusionsproteine des reproduktiven und respiratorischen syndrom virus aus dem schwein als prrs impfstoff

Info

Publication number
ATE550033T1
ATE550033T1 AT06253982T AT06253982T ATE550033T1 AT E550033 T1 ATE550033 T1 AT E550033T1 AT 06253982 T AT06253982 T AT 06253982T AT 06253982 T AT06253982 T AT 06253982T AT E550033 T1 ATE550033 T1 AT E550033T1
Authority
AT
Austria
Prior art keywords
pqgab
prrsv
kdel
vaccine
pork
Prior art date
Application number
AT06253982T
Other languages
English (en)
Inventor
Hsiu-Kang Chang
Chao-Wei Liao
Original Assignee
Healthbanks Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Healthbanks Biotech Co Ltd filed Critical Healthbanks Biotech Co Ltd
Application granted granted Critical
Publication of ATE550033T1 publication Critical patent/ATE550033T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10071—Demonstrated in vivo effect

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT06253982T 2006-07-29 2006-07-29 Fusionsproteine des reproduktiven und respiratorischen syndrom virus aus dem schwein als prrs impfstoff ATE550033T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06253982A EP1882478B1 (de) 2006-07-29 2006-07-29 Fusionsproteine des reproduktiven und respiratorischen Syndrom Virus aus dem Schwein als PRRS Impfstoff

Publications (1)

Publication Number Publication Date
ATE550033T1 true ATE550033T1 (de) 2012-04-15

Family

ID=37517616

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06253982T ATE550033T1 (de) 2006-07-29 2006-07-29 Fusionsproteine des reproduktiven und respiratorischen syndrom virus aus dem schwein als prrs impfstoff

Country Status (3)

Country Link
EP (1) EP1882478B1 (de)
AT (1) ATE550033T1 (de)
ES (1) ES2384524T3 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI417385B (zh) * 2010-05-04 2013-12-01 Univ Nat Taiwan 以植物生產之豬生殖與呼吸道綜合症口服疫苗及其用途
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
WO2016196383A1 (en) 2015-06-01 2016-12-08 Reber Genetics Co., Ltd. Vaccine compositions against porcine reproductive and respiratory syndrome and porcine circovirus associated diseases
SG11202009925PA (en) 2018-03-08 2020-11-27 Applied Molecular Transport Inc Toxin-derived delivery constructs for oral delivery
IL282986B2 (en) 2018-11-07 2024-01-01 Applied Molecular Transport Inc Colics-derivative carriers for oral administration of heterologous cargo
CN113046329B (zh) * 2020-11-10 2024-01-30 山东省滨州畜牧兽医研究院 猪繁殖与呼吸障碍综合征病毒嵌合重组的PRRSV DIVA疫苗株cDY56

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7335361B2 (en) * 2003-06-09 2008-02-26 Animal Technology Institute Taiwan Fusion antigen used as vaccine

Also Published As

Publication number Publication date
ES2384524T3 (es) 2012-07-06
EP1882478B1 (de) 2012-03-21
EP1882478A1 (de) 2008-01-30

Similar Documents

Publication Publication Date Title
CA2572555A1 (en) Fusion protein of porcine reproductive and respiratory syndrome virus as prrs vaccine
ATE550033T1 (de) Fusionsproteine des reproduktiven und respiratorischen syndrom virus aus dem schwein als prrs impfstoff
CY1119265T1 (el) Κατασκευες νανοσωματων τρισθενους αντι ανθρωπινου αναπνευστικου συγκυτιακου ιου (hrsv) για την προληψη και/ή θεραπεια λοιμωξεων της αναπνευστικης οδου
BRPI0516951A2 (pt) isolados da sÍndrome respiratària e reprodutora suÍna e mÉtodos de uso
WO2010074575A3 (en) Recombinant classical swine fever virus (csfv) comprising a modified e2 protein and methods for generating said recombinant csfv.
RU2015122368A (ru) Слитые белки для применения в качестве иммуногенных усиливающих агентов для индуцирования антигенспецифического т-клеточного ответа
JP2009537143A5 (de)
ATE365746T1 (de) Prrsv-antigene, die auf peptidsequenzen des prrs- virus basieren, für die verwendung als impfstoff und für diagnostische tests
MX2014007894A (es) Vacuna de marcadores basados en peptidos sinteticos y sistema de diagnostico para el control efectivo del sindrome reproductivo y respiratorio porcino (prrs).
WO2005120565A8 (en) Sars vaccines and methods to produce highly potent antibodies
JP2011500035A5 (de)
WO2005081716A3 (en) DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV)
WO2008134697A3 (en) Prrsv vaccins based on gp5 proteins
CA2516511C (en) Fusion protein for inhibiting cervical cancer
WO2022032660A1 (zh) 新型冠状病毒rbd融合蛋白
JP2016504993A5 (de)
Zhu et al. A bacteriophage-based, highly efficacious, needle-and adjuvant-free, mucosal COVID-19 vaccine
EP2502998A3 (de) Rekombinanter Toxin A-/Toxin B-Impfstoff gegen Clostridium difficile
Baldeon Vaca et al. Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection
ATE527237T1 (de) Modifizierter mscl-proteinkanal
RU2005123050A (ru) Супер-антигенные фьюжн-белки и их использование
Greene et al. LT-IIb (T13I), a non-toxic type II heat-labile enterotoxin, augments the capacity of a ricin toxin subunit vaccine to evoke neutralizing antibodies and protective immunity
Alexander et al. CBirTox is a selective antigen-specific agonist of the Treg-IgA-microbiota homeostatic pathway
Cacciottolo et al. Nanograms of SARS-CoV-2 spike protein delivered by exosomes induce potent neutralization of both delta and omicron variants
WO2006007366A3 (en) SKIN IMMUNIZATION USING LT-STa FUSION PROTEINS